- Article
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
- Conor J. Gallagher,
- Ronald R. Bowsher,
- Amanda Clancy,
- Jeffrey S. Dover,
- Shannon Humphrey,
- Yan Liu and
- Gregg Prawdzik
DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004). DAXI immunogenicity was assessed in three phase 3 glabellar line studies (two placebo-con...

